Citi upgraded Glaukos (GKOS) to Buy from Neutral with a price target of $162, up from $132. Glaukos appears to have successfully launched iDose, and it is now executing on its broader portfolio, the analyst tells investors in a research note. With iDose sales likely inflecting next year along with a steady cadence of catalysts, Citi upgraded the shares.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS: